Cleveland Clinic and Dyania’s Work on AI in Clinical Trial Matching Earns 2026 Gartner Eye on Innovation Award

Cleveland Clinic was awarded a 2026 Gartner Eye on Innovation Award for its collaboration with Dyania Health using artificial intelligence to speed up patient identification for clinical trials. The Gartner EOI is the world's leading competition that honors organizations for innovative use of technology to drive best-in-class initiatives.

Cleveland Clinic is recognized in the Healthcare and Life Sciences category for its work with Dyania Health's Synapsis Artificial Intelligence (AI) Platform. The relationship with Dyania started with successful pilot programs in cardiology and oncology and has grown into other areas.

Synapsis AI is a physician-grade AI platform designed to read and interpret structured and unstructured electronic medical records data at scale. The tool's automated matching process reduces the manual workload of patient screening, while ensuring the precise identification of patients based on complex eligibility criteria. This process shortens recruitment timelines and improves clinical trial recruitment efforts and outcomes.

“Innovation in healthcare is about more than adopting new technology. It is about finding better ways to connect patients to the care and opportunities that can improve lives,” said Lara Jehi, M.D., Cleveland Clinic’s Chief Research Information Officer. “This collaboration demonstrates how innovative technology can help remove barriers in the clinical trial process, support our care teams and expand access to research. We are proud to be recognized for advancing solutions that help us continually improve healthcare for patients and communities.”

Synapsis AI was deployed across the enterprise in November 2025, supporting rare disease trial recruitment and trials with challenging criteria. On average, study teams have enrolled 40% more patients 47% faster with the platform.

The AI-assisted screening translates to broadening access to trials, supporting enrollment across populations while reducing staff burden and allowing coordinators to focus on patient engagement and care. This technology has helped recruit patients with rare diseases, such as advanced esophageal adenocarcinoma, myeloma and intestinal failure.